These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 9175717)
1. Effects of synthetic oligonucleotides on human complement and coagulation. Shaw DR; Rustagi PK; Kandimalla ER; Manning AN; Jiang Z; Agrawal S Biochem Pharmacol; 1997 Apr; 53(8):1123-32. PubMed ID: 9175717 [TBL] [Abstract][Full Text] [Related]
2. Novel enzymatic and immunological responses to oligonucleotides. Agrawal S; Rustagi PK; Shaw DR Toxicol Lett; 1995 Dec; 82-83():431-4. PubMed ID: 8597089 [TBL] [Abstract][Full Text] [Related]
3. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Sheehan JP; Lan HC Blood; 1998 Sep; 92(5):1617-25. PubMed ID: 9716589 [TBL] [Abstract][Full Text] [Related]
4. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Gao WY; Han FS; Storm C; Egan W; Cheng YC Mol Pharmacol; 1992 Feb; 41(2):223-9. PubMed ID: 1371582 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of coagulation by a phosphorothioate oligonucleotide. Henry SP; Novotny W; Leeds J; Auletta C; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):503-10. PubMed ID: 9361909 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of mouse hepatitis virus multiplication by phosphorothioate analogues of oligodeoxynucleotides complementary to the leader RNA. Hayashi M; Maeda A; Watanabe T; Hanaki K; Arai S; Nozaki S J Vet Med Sci; 1995 Dec; 57(6):1081-3. PubMed ID: 8720052 [TBL] [Abstract][Full Text] [Related]
7. Antisense inhibitory effect: a comparison between 3'-partial and full phosphorothioate antisense oligonucleotides. Galderisi U; Di Bernardo G; Melone MA; Galano G; Cascino A; Giordano A; Cipollaro M J Cell Biochem; 1999 Jul; 74(1):31-7. PubMed ID: 10381259 [TBL] [Abstract][Full Text] [Related]
8. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys. Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591 [TBL] [Abstract][Full Text] [Related]
9. Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains. Rapaport E; Levina A; Metelev V; Zamecnik PC Proc Natl Acad Sci U S A; 1996 Jan; 93(2):709-13. PubMed ID: 8570621 [TBL] [Abstract][Full Text] [Related]
10. Design of potent phosphorothioate antisense oligonucleotides directed to human interleukin 10 gene product and their evaluation of antisense activity in U937 cells. Arima H; Takahashi M; Aramaki Y; Sakamoto T; Yuda K; Akiyama K; Goto T; Tsuchiya S Pharm Res; 1999 Aug; 16(8):1163-71. PubMed ID: 10468015 [TBL] [Abstract][Full Text] [Related]
12. Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation. Kandimalla ER; Shaw DR; Agrawal S Bioorg Med Chem Lett; 1998 Aug; 8(16):2103-8. PubMed ID: 9873494 [TBL] [Abstract][Full Text] [Related]
13. Pseudo-cyclic oligonucleotides: in vitro and in vivo properties. Jiang Z; Kandimalla ER; Zhao Q; Shen LX; DeLuca A; Normano N; Ruskowski M; Agrawal S Bioorg Med Chem; 1999 Dec; 7(12):2727-35. PubMed ID: 10658577 [TBL] [Abstract][Full Text] [Related]
14. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation. Chang LC; Lee HF; Chung MJ; Yang VC Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats. Stepkowski SM; Qu X; Wang ME; Tian L; Chen W; Wancewicz EV; Johnston JF; Bennett CF; Monia BP Transplantation; 2000 Aug; 70(4):656-61. PubMed ID: 10972225 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of modified oligonucleotides complementary to the leader RNA on the multiplication of mouse hepatitis virus. Hayashi M; Maeda A; Kihara M; Arai S; Hanaki K; Nozaki T Adv Exp Med Biol; 1998; 440():701-5. PubMed ID: 9782347 [TBL] [Abstract][Full Text] [Related]
17. P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Krieg AM; Guga P; Stec W Oligonucleotides; 2003; 13(6):491-9. PubMed ID: 15025915 [TBL] [Abstract][Full Text] [Related]
18. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Holmlund JT; Monia BP; Kwoh TJ; Dorr FA Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802 [TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140 [TBL] [Abstract][Full Text] [Related]
20. Multimeric tyrosine sulfate acts as an endothelial cell protectant and prevents complement activation in xenotransplantation models. Laumonier T; Walpen AJ; Matozan KM; Korchagina EY; Bovin NV; Haeberli A; Mohacsi PJ; Rieben R Xenotransplantation; 2004 May; 11(3):262-8. PubMed ID: 15099206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]